Thyroid cancer in the age of COVID-19

COVID-19 has modified the way we practice medicine. For thyroid cancer, there have been several significant impacts. First, the diagnosis has been delayed due to social isolation, reduced access to investigations and staff redeployment. Secondly, treatment planning has needed to take into account th...

Full description

Saved in:
Bibliographic Details
Published inEndocrine-related cancer Vol. 27; no. 11; pp. R407 - R416
Main Authors Tsang, Venessa H M, Gild, Matti, Glover, Anthony, Clifton-Bligh, Roderick, Robinson, Bruce G
Format Journal Article
LanguageEnglish
Published England Bioscientifica Ltd 01.11.2020
Society for Endocrinology & BioScientifica Ltd
Subjects
Betacoronavirus
Coronavirus Infections - epidemiology
Coronaviruses
COVID-19
Delayed Diagnosis
Disease transmission
Hospitals
Humans
Iodine Radioisotopes - therapeutic use
Pandemics
Pneumonia, Viral - epidemiology
Protein Kinase Inhibitors - therapeutic use
Review
SARS-CoV-2
Social interactions
Thyroid cancer
Thyroid Neoplasms - diagnosis
Thyroid Neoplasms - therapy
COVID-19
radioactive iodine
thyroid cancer
tyrosine kinase inhibitor
Online AccessGet full text

Cover

More Information
Summary:COVID-19 has modified the way we practice medicine. For thyroid cancer, there have been several significant impacts. First, the diagnosis has been delayed due to social isolation, reduced access to investigations and staff redeployment. Secondly, treatment planning has needed to take into account the risk to patients and/or staff of nosocomial transmission of the virus. Finally, there are some specific concerns with respect to interactions between the virus, its treatments and cancer. This mini-review aims to address each of these impacts and to provide some guidance and confidence to our patients and colleagues during this challenging time.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1351-0088
1479-6821
DOI:10.1530/ERC-20-0279